In a parallel development, J&J and Legend Biotech are gearing up for an FDA meeting in the United States to discuss the expansion of Carvytki into earlier lines of treatment. Legend Biotech CEO, Ying Huang, anticipates that the meeting will predominantly scrutinize overall survival data, despite ongoing concerns about safety associated with CAR-T therapy, particularly the risk of secondary T-cell cancers.
This focus on overall survival underscores the FDA’s recent emphasis on using it as a composite metric for both efficacy and safety evaluation. While Carvytki has demonstrated promising survival benefits, concerns linger regarding potential toxicities, prompting thorough deliberation during regulatory reviews.
Meanwhile, Bristol Myers Squibb (BMS) faces challenges with their CAR-T therapy, Abecma, which failed to exhibit a significant extension in overall survival compared to standard treatments. The FDA remains cautious about negative trends in overall survival, even if attributed to patient crossover in clinical trials.
J&J and Legend remain optimistic about Carvytki’s potential, concurrently addressing manufacturing challenges to ensure product quality and consistency. However, ongoing safety and efficacy concerns underscore the critical need for comprehensive evaluation and discussion in upcoming regulatory proceedings on both sides of the Atlantic.
https://www.fiercepharma.com/pharma/legend-ceo-offers-preview-high-profile-fda-adcomm-jj-partnered-carvykti
https://www.biospace.com/article/eu-regulators-back-j-and-j-legend-s-carvykti-for-second-line-multiple-myeloma-ahead-of-adcomm/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services